Covid: Valneva reports positive results for their phase 3 candidate vaccine

Published by Manon C. · Updated on 18 October 2021 at 10h37 · Published on 18 October 2021 at 09h37
The French-Austrian laboratory Valneva has announced "positive topline results" for their Covid vaccine currently completing phase 3 of the clinical trial.

This Monday October 18, 2021, French-Austrian laboratory Valneva announced their Covid candidate vaccine - currently completing phase 3 of clinical trial - showed "positive ropline results".

"The trial met its co-primary endpoints", the press release reads while specifying the vaccine "demonstrated superiority against AZD1222 (AstraZeneca), in terms of geometric mean titer for neutralization antibodies, as well as non-inferiority in terms of seroconversion rates (SCR above 95% in both treatment groups) at two weeks after the second vaccination (i.e. Day 43) in adults aged 30 years and older."

The phase 3 of the trial has been performed in 4,012 people aged 18+ and the vaccine has been "generally well tolerated": "The tolerability profile of VLA2001 was significantly more favorable compared to the active comparator vaccine."

For the record, the vaccine relies on the inactivated virus” technology, the standard form of vaccines so far, like products developed by Sinovac and Sinopharm. "This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America and these results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic", Adam Finn, Professor of Paediatrics, University of Bristol, Trial Chief Investigator, said.

This new vaccine could be licensured "as quickly as possible" to "propose an alternative vaccine solution for people who have not yet been vaccinated", Thomas Lingelbach, Chief Executive Officer of Valneva, said. Furthermore, the laboratory announced they have "commenced rolling submission for initial approval with the UK’s Medicines and Healthcare products Regulatory Agency" as well as "preparing to commence rolling submission for conditional approval with the European Medicines Agency".

Practical information

Comments
Refine your search
Refine your search
Refine your search
Refine your search